http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
-
Genelux Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
-
Genelux (GNLX) and Newsoara Announce Positive Preliminary Phase 1b/2 Data of Olvi-Vec in Advanced Small-Cell Lung Cancer
-
Genelux and Newsoara Announce Positive Preliminary Phase 1b/2 Data of Olvi-Vec in Advanced Small-Cell Lung Cancer
-
Genelux (GNLX) Appoints Matthew Pulisic as CFO
-
Genelux Corporation Announces New Chief Financial Officer
-
Genelux Corporation to Participate in a Fireside Chat with H.C. Wainwright
-
Genelux Corporation Reports Third Quarter 2024 Financial Results and Provides General Business Updates
-
Genelux Corporation to Participate in Fireside Chat at the Guggenheim Inaugural Healthcare Innovation Conference
-
Genelux (GNLX) Announces First Patient Dosed in Phase 2 Trial Evaluating Systemic Therapy with Olvi-Vec in Non-Small Cell Lung Cancer
-
Genelux Corporation Announces First Patient Dosed in Phase 2 Trial Evaluating Systemic Therapy with Olvi-Vec in Non-Small Cell Lung Cancer
-
Genelux Corporation to Participate in the 2024 Maxim Healthcare Virtual Summit
-
Genelux Corporation to Present at the H.C. Wainwright Global Investment Conference
-
Genelux Corporation Reports Second Quarter 2024 Financial Results and Provides General Business Updates
-
Genelux Corporation to Participate in Fireside Chat at BTIG’s Virtual Biotechnology Conference 2024
-
Genelux Corporation Reports First Quarter 2024 Financial Results and Provides General Business Updates
-
Genelux Corporation Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
-
Genelux (GNLX) Receives FDA Fast Track Designation for Olvi-Vec in Platinum Resistant/Refractory Ovarian Cancer
-
Genelux Corporation Receives FDA Fast Track Designation for Olvi-Vec in Platinum Resistant/Refractory Ovarian Cancer
-
Genelux Corporation Reports Third Quarter 2023 Financial Results and Provides General Business Updates
-
Genelux Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Genelux Corporation to Present at the H.C. Wainwright Global Investment Conference
-
Genelux Corporation Announces New Chief Financial Officer
-
Genelux Corporation Reports Second Quarter 2023 Financial Results and Provides General Business Updates
-
Genelux Corporation to Participate in Fireside Chat at BTIG’s Virtual Biotechnology Conference 2023
-
Genelux (GNLX) Announces Management Changes
-
Genelux Corporation Strengthens Senior Management and Clinical Team with Promotions and New Hires
-
Genelux (GNLX) to Join the Russell 3000 and Russell 2000 Indexes
-
Genelux Corporation Set to Join the Russell 3000® and Russell 2000® Indexes Effective June 26, 2023
-
Genelux Corporation to Ring Nasdaq Opening Bell on March 29, 2023
-
Genelux Corporation to Ring Nasdaq Opening Bell on March 29, 2023

